A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This open-label, non-comparative, multi-center study will assess the safety profile and
efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in
participants with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal
carcinoma. Participants will receive 15 milligrams/kilogram (mg/kg) Avastin intravenously
(IV) on Day 1 of every cycle for up to 36 cycles of 3 weeks each, carboplatin (area under the
plasma concentration-time curve [AUC] 5-6 mg/ml/min) on Day 1 every 3 weeks for a maximum of
8 cycles and paclitaxel 175 milligram per square meter (mg/m^2) on Day 1 every 3 weeks or 80
mg/m^2 every week for a maximum of 8 cycles. The anticipated time on study drug will be 108
weeks or until disease progression or unacceptable toxicity.